Fushine Pharmaceuticals released its performance for the first half of the year, with a net loss attributable to the parent company of 6.9112 million yuan, narrowing by 69.23%
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Fushine Pharmaceuticals released its semi-annual report for 2025, showing an operating income of 515 million yuan, a year-on-year decrease of 24.58%. The net loss attributable to shareholders of the listed company was 6.9112 million yuan, a year-on-year narrowing of 69.23%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 32.1798 million yuan, a year-on-year narrowing of 34.91%. The basic loss per share was 0.01 yuan
According to the Zhitong Finance APP, Fushine (300497.SZ) released its semi-annual report for 2025, showing an operating income of 515 million yuan, a year-on-year decrease of 24.58%. The net loss attributable to shareholders of the listed company was 6.9112 million yuan, a year-on-year narrowing of 69.23%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 32.1798 million yuan, a year-on-year narrowing of 34.91%. The basic loss per share was 0.01 yuan